OvaCure Live at the NSGO Nordic Hotspot for Rare Tumours in Gynaecological Cancers

OvaCure is excited to participate in the NSGO Annual Meeting in Helsinki, Finland today. With more than 70 international gyno-oncological experts in one room, we have a front seat to new knowledge exchange and innovation in ovarian cancer clinical research.

OvaCure is a proud collaboration partner with the Nordic Society of Gynaecological Oncology - we share successes which bring us closer to the cure for women with ovarian cancer.

Innovation in Standard of Care: PARP Inhibitors Approved for All Patients

On the 27th of March 2017, Tesaro’s PARP inhibitor named Zejula received FDA regulatory approval for the treatment of all recurrent epithelial ovarian cancer patients - irrespective of their BRCA 1/2 status. This is a major contribution to the current treatment regimen for these patients, who previously had less than a 30% chance of qualifying for treatment with this life-prolonging drug.

 

This paradigm shift in care was initiated by the results generated from the 553-patient NOVA study led by OvaCure’s collaborating principal investigator, Dr. Mansoor Raza Mirza. The trial revealed that all patients experienced significant clinical benefit from treatment with PARP inhibitors. Progression-free survival for patients treated with Zejula was up to 21 months. While those treated with a placebo, experienced a maximum of 5.5 months without progression of the disease.

This approval provides future relapsed patients with hope of better management of their disease, improved quality of life and a step closer to the cure. European approval of the use of Zejula for all epithelial ovarian cancer patients is currently under review.

OvaCure is proud to collaborate with Principal Investigator of this trial, Dr. Mansoor Raza Mirza in our Tumour-Match Project. 

ESMO Guidelines on Ovarian Cancer Care by Professor Jonathan Ledermann

A comprehensive review of the options available for the treatment of recurrent disease and discuss how different agents are selected, combined and offered in a rationale sequence in the context of multidisciplinary care. Published work between 1990 and 2013 and meeting abstracts are related to the use of chemotherapy and surgery in patients with recurrent ovarian cancer.

Professor Charlie Gourley on Advances in Ovarian Cancer Maintenance Therapy

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discuses olaparib (Lynparza), which was recently investigated in a phase II Study 19 trial versus placebo as a maintenance therapy for patients with relapsed platinum-sensitive serous ovarian cancer.

The drug really works, says Gourley. The study was designed to look at progression-free survival (PFS), and, unequivocally, it clearly showed that this drug improved PFS, he says.  
 

Professor Inge Marie Svane is breaking new ground with Immunotherapy

Ugeskr Læger 178/17 22. august 2016

20 years ago, as a medical intern, Inge Marie Svane never would have guessed that she would be apart of the scientific breakthroughs which are today improving survival rates for cancer patients. Immunotherapy has been proclaimed to be the key to treat patients with a various cancer forms. Professor Svane is currently principal investigator for several clinical trials applying cellular-based immunotherapy to patients with metastatic melanoma, renal cell and ovarian cancers - offering the most promising hope for patients with advanced stage disease.

OvaCure's Dr. Mansoor Raza Mirza improving survival and shifting paradigms for ovarian cancer patients

The ASCO Post, 8th October 2016.

Mansoor Raza Mirza, MD,  Chief Oncologist of Rigshospitalet, Copenhagen University Hospital, impresses the crowd at ESMO 2016, Denmark with his phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. 

Immunotherapeutic approaches to ovarian cancer treatment

By Late Holbrook Kohrt et. al. (2015.03.24)
Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

  OvaCure's co-founder, Late Associate Professor Holbrook Kohrt

OvaCure's co-founder, Late Associate Professor Holbrook Kohrt

Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. 

Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.

T-cell therapy offers lasting cure prospects, scientists say

OvaCure supports advances in immunotherapy approaches. It has shown great results in some cancer forms and OvaCure scientist are now applying T-cell therapy treatments in ovarian cancer patients - for the first time in the world.

Immunotherapy approaches are currently being tested in the clinical phases of several trials, yet there is great hope in its potential to cure cancer patients.

"A revolutionary cancer therapy that uses the body’s own immune cells to attack metastatic tumours that have spread is being hailed as a “paradigm shift” in treatment of the disease."